GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hunan Er-Kang Pharmaceutical Co Ltd (SZSE:300267) » Definitions » EV-to-Revenue

Hunan Er-Kang Pharmaceutical Co (SZSE:300267) EV-to-Revenue : 2.61 (As of Apr. 29, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Hunan Er-Kang Pharmaceutical Co EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Hunan Er-Kang Pharmaceutical Co's enterprise value is ¥4,654 Mil. Hunan Er-Kang Pharmaceutical Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was ¥1,783 Mil. Therefore, Hunan Er-Kang Pharmaceutical Co's EV-to-Revenue for today is 2.61.

The historical rank and industry rank for Hunan Er-Kang Pharmaceutical Co's EV-to-Revenue or its related term are showing as below:

SZSE:300267' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.35   Med: 4.06   Max: 29.87
Current: 2.61

During the past 13 years, the highest EV-to-Revenue of Hunan Er-Kang Pharmaceutical Co was 29.87. The lowest was 2.35. And the median was 4.06.

SZSE:300267's EV-to-Revenue is ranked worse than
54.3% of 1024 companies
in the Drug Manufacturers industry
Industry Median: 2.295 vs SZSE:300267: 2.61

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-29), Hunan Er-Kang Pharmaceutical Co's stock price is ¥2.54. Hunan Er-Kang Pharmaceutical Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was ¥0.87. Therefore, Hunan Er-Kang Pharmaceutical Co's PS Ratio for today is 2.94.


Hunan Er-Kang Pharmaceutical Co EV-to-Revenue Historical Data

The historical data trend for Hunan Er-Kang Pharmaceutical Co's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hunan Er-Kang Pharmaceutical Co EV-to-Revenue Chart

Hunan Er-Kang Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.41 3.48 4.16 3.66 3.47

Hunan Er-Kang Pharmaceutical Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.66 3.33 3.05 3.32 3.47

Competitive Comparison of Hunan Er-Kang Pharmaceutical Co's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Hunan Er-Kang Pharmaceutical Co's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hunan Er-Kang Pharmaceutical Co's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hunan Er-Kang Pharmaceutical Co's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Hunan Er-Kang Pharmaceutical Co's EV-to-Revenue falls into.



Hunan Er-Kang Pharmaceutical Co EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Hunan Er-Kang Pharmaceutical Co's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=4654.127/1783.118
=2.61

Hunan Er-Kang Pharmaceutical Co's current Enterprise Value is ¥4,654 Mil.
Hunan Er-Kang Pharmaceutical Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1,783 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hunan Er-Kang Pharmaceutical Co  (SZSE:300267) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Hunan Er-Kang Pharmaceutical Co's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=2.54/0.865
=2.94

Hunan Er-Kang Pharmaceutical Co's share price for today is ¥2.54.
Hunan Er-Kang Pharmaceutical Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.87.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hunan Er-Kang Pharmaceutical Co EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Hunan Er-Kang Pharmaceutical Co's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Hunan Er-Kang Pharmaceutical Co (SZSE:300267) Business Description

Traded in Other Exchanges
N/A
Address
Kangping Road 167, National Economic and Technological Development Zone, Liuyang Changsha, Hunan, CHN, 410331
Hunan Er-Kang Pharmaceutical Co Ltd develops, produces and sells pharmaceutical products in China. The company's main products include pharmaceutical excipients and antibiotics. It offers pharmaceutical excipients, APIs and finished drug products. The pharmaceutical excipients include products such as glycerol, ethanol pharmaceutically, acceptable propylene glycol, sodium hydroxide, and pharmaceutically acceptable sugar. The company's finished drugs primarily include sulbenicillin sodium for injection and compound liquorice tablets. Its APIs include glycerin, dilute hydrochloric acid, dihydroxypropyl theophylline, sulbenicillin sodium, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. Geographically, all the activities are carried out through China.

Hunan Er-Kang Pharmaceutical Co (SZSE:300267) Headlines

No Headlines